Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698984 | Clinical Oncology | 2013 | 7 Pages |
Abstract
The efficacy of degarelix in terms of prostate shrinkage is non-inferior to that of goserelin plus bicalutamide. The added benefits of degarelix in terms of more pronounced lower urinary tract symptom relief in symptomatic patients could be the reflection of differences in the direct effects on extra-pituitary receptors in the lower urinary tract [Clinicaltrials.gov ID: NCT00833248].
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M. Mason, X. Maldonado Pijoan, C. Steidle, S. Guerif, T. Wiegel, E. van der Meulen, P.B.F. Bergqvist, V. Khoo,